Manuel Drost

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents—A Prospective Cohort Study of the AGMT Study-Group

L. Pleyer, R. Greil, S. Machherndl-Spandl, 2022, Cancers.

Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine—A Prospective Cohort Study by the AGMT

L. Pleyer, R. Greil, J. Hasenauer, 2023, Cancers.

Surface characterization determined from the secondary electron emission coefficient upon ion bombardment

P. Scheier, A. Menzel, Felix Duensing, 2021, Applied Surface Science.

Myeloid NGS Analyses of Paired Samples from Bone Marrow and Peripheral Blood Yield Concordant Results: A Prospective Cohort Analysis of the AGMT Study Group

L. Pleyer, R. Greil, A. Risch, 2023, Cancers.

Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.

L. Pleyer, R. Greil, J. Hasenauer, 2023, American journal of hematology.

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

L. Pleyer, R. Greil, C. Schmitt, 2021, Blood.

A randomized, double-blind study on the safety and immunogenicity of rTSST-1 variant vaccine: phase 2 results

A. Roetzer, C. Schoergenhofer, U. Derhaschnig, 2024, EClinicalMedicine.